NeoTX

Company Overview

Snapshot

Founded in April 2015, NeoTX operates with 11–50 employees. The company has raised $65.5M across 4 funding rounds from 5 investors. In May 2022, NeoTX acquired InterX, enhancing its discovery capabilities.

Business overview

NeoTX is a biopharmaceutical company focused on developing targeted anticancer immunotherapies using its proprietary Selective T cell Redirection (STR) platform. This technology genetically engineers a bacterial determinant to bind to tumor surfaces, activating immune cells to mount an effective antibacterial response against cancer. The company's lead STR molecule, Naptumomab estafenatox, is currently in clinical development for advanced solid tumors, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals.

Strategic signal

In June 2022, NeoTX announced the successful first stage completion of its Phase 2a clinical trial for naptumomab estafenatox (NAP) in combination with docetaxel for advanced non-small cell lung cancer (NSCLC). This milestone provides a strong signal of progress in the clinical development of its lead immunotherapy candidate, validating its potential in a significant cancer indication and demonstrating advancement towards commercialization.

Company Intelligence Q&A

What is NeoTX's core technology?

NeoTX leverages its proprietary Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies. This technology redirects immune cells to target tumors by binding a genetically engineered bacterial determinant to the tumor surface.

When did NeoTX complete the first stage of its Phase 2a clinical trial for naptumomab estafenatox?

In June 2022, NeoTX announced the successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP) in combination with docetaxel for advanced non-small cell lung cancer (NSCLC).

What was a significant corporate development for NeoTX in 2022?

In May 2022, NeoTX acquired InterX, a move that added a world-class discovery arm to the company's capabilities.

When did NeoTX promote Marcel Rozencweig to President?

In January 2022, NeoTX Therapeutics promoted Marcel Rozencweig, M.D., to President and welcomed Scott Z. Fields, M.D., as the new Chief Medical Officer.

Which investors participated in NeoTX's February 2020 funding round?

In February 2020, NeoTX received funding from investors J. Tomilson Hil and Tako Ventures.